** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at A$4.135, set for a fourth consecutive session of gain
** Radiopharma co says the U.S. Food and Drug Administration has granted Fast Track Designation for its prostate cancer drug, 64Cu-SAR-bisPSMA
** Says the drug has several advantages over currently approved ones, including improved diagnostic performance and flexible imaging schedule, among others
** Stock rises as much as 15.5% earlier in the day, marking its biggest intraday pct gain since Dec. 18, 2024
** About 2 mln shares change hands, 1.1x the 30-avg
** Stock more than doubled in value last year
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。